Pediatric pulmonology
Pediatric pulmonology
Audio Summaries
Every issue of Pediatric pulmonology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Pediatric pulmonology.
Efficacy of High Flow Nasal Cannula in Reducing Hypoxemia in Children Undergoing Elective Flexible Fibreoptic Bronchoscopy as Compared to Conventional Low Flow Nasal Cannula: A Randomized Controlled Trial
Jun 11, 2026
This study aimed to evaluate the efficacy and safety of high-flow nasal cannula (HFNC) compared to low-flow nasal cannula (LFNC) in preventing hypoxemia during elective flexible fibreoptic bronchoscopy (FFB) in children. The results indicated no significant difference in hypoxemia rates between the two groups, suggesting that HFNC does not provide a clear advantage over LFNC in this context, although the study may have lacked sufficient power to detect smaller differences.
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants
Jun 11, 2026
This study aimed to evaluate the impact of newly implemented RSV preventive strategies, including nirsevimab and a vaccine for pregnant women, on the clinical severity and viral epidemiology of bronchiolitis in hospitalized infants. The findings indicated that post-intervention infants experienced milder illness, shorter hospital stays, and lower rates of RSV infection compared to pre-intervention infants, suggesting a positive effect of these preventive measures. Additionally, the study highlights the need for ongoing surveillance to assess the long-term outcomes of these interventions.
Real-World Clinical Outcomes of Lumacaftor-Ivacaftor or Tezacaftor-Ivacaftor Therapy in Children With Cystic Fibrosis Homozygous for Phe508del
Jun 11, 2026
This study aims to evaluate the real-world clinical outcomes of dual CFTR modulator therapy (lumacaftor/ivacaftor or tezacaftor/ivacaftor) in children with cystic fibrosis who are homozygous for the Phe508del mutation. The findings indicate a significant reduction in sweat chloride concentration and modest improvements in lung function after one year of treatment, while other health parameters remained stable, supporting the therapy's efficacy and safety in pediatric patients.